In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Learn how Huntsman Cancer Institute uses cutting‑edge diagnostics and personalized care to treat early‑stage prostate cancer. Discover why early detection makes treatment more effective and far less ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants published by Wiley online in CANCER, investigators found ...

Baseline T may provide valuable information about prognosis.

No increased risk for thrombosis or bleeding seen with concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs.

Prostate enlargement, which is called Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement and is common in ...

A new research paper was published in Volume 13 of Oncoscience on February 7, 2026, titled “Reduced immunogenicity of MYC amplified, metastatic prostate cancer.” ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...

Experts urge caution in interpreting results of a small pilot study finding microplastics in prostate cancer tissue, calling the results provocative but preliminary.